Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Majestec-2 Cohort a and Trimm-2 Studies

Blood (2024) 144 (Supplement 1): 495.

https://doi.org/10.1182/blood-2024-200181

Published: 2024

Journal Articles

MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial

Blood (2024) 144 (Supplement 1): 2000.1.

https://doi.org/10.1182/blood-2024-200210

Published: 2024

Journal Articles

Analysis of Repeat Step-up Dosing and Cytokine Release Syndrome Events Following Prolonged Dosing Intervals of Teclistamab in the Phase 1/2 Majestec-1 Study

Blood (2024) 144 (Supplement 1): 4734.

https://doi.org/10.1182/blood-2024-200344

Published: 2024

Journal Articles

Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies

Blood (2024) 144 (Supplement 1): 4653.

https://doi.org/10.1182/blood-2024-200333

Published: 2024

Journal Articles

Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide

Blood (2024) 144 (Supplement 1): 594.

https://doi.org/10.1182/blood-2024-200300

Published: 2024

Journal Articles

Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC TM Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Binod Dhakal, Andrew J. Yee, Paul G. Richardson, Sikander Ailawadhi, Saurabh Chhabra, Eli Muchtar, Jesús G. Berdeja, Shambavi Richard, Jeffrey V Matous, Urvi A. Shah, Mark A. Schroeder, Amro Ali, Leah Leahy, Riadh Lobbardi, Rong Chu, Eunju Hurh, Anthony S. Fiorino, Sagar Lonial

Blood (2024) 144 (Supplement 1): 3366.

https://doi.org/10.1182/blood-2024-204255

Published: 2024

Journal Articles

Phase II Study of Isatuximab, and Weekly Carfilzomib + Dexamethasone in Relapsed and Refractory Multiple Myeloma (RRMM)

David H. Vesole, Thomas G Martin, Suzanne Trudel, Henning Schade, Samantha Shenoy, Noa Biran, Jeffrey Lee Wolf, Jeffrey V Matous, Pamela Munster, Savannah Berkeley, Jesús G Berdeja

Blood (2024) 144 (Supplement 1): 1982.

https://doi.org/10.1182/blood-2024-209597

Published: 2024

Journal Articles

Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Combination with Daratumumab and Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma: Safety and Efficacy Results from the Phase 1b Monumental-2 Study

Ajay K. Nooka, Tara Cochrane, Anita D'Souza, Jeffrey V Matous, Peter M. Voorhees, Karthik Ramasamy, Aurore Perrot, Andrew Spencer, Cyrille Hulin, Hang Quach, Deeksha Vishwamitra, Ashley Nguyen, Debopriya Ghosh, Elizabeth Shearin, Gary E Mason, Thomas Renaud, Gurdeep Parmar

Blood (2024) 144 (Supplement 1): 1975.

https://doi.org/10.1182/blood-2024-199773

Published: 2024

Journal Articles

Higher Teclistamab Step-up Dosing in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Results from the Majestec-1 Trial

Jeffrey V Matous, Niels W.C.J. van de Donk, Albert Oriol, Alfred L. Garfall, Paula Rodríguez-Otero, Thomas Chalopin, Laura Rosinol Dachs, Katarina Uttervall, Maria- Victoria Mateos, Danielle Trancucci, Natalia Quijano Cardé, Caroline Hodin, Tara Stephenson, Athena Zuppa, Katherine Chastain, Lionel Karlin

Blood (2024) 144 (Supplement 1): 4749.

https://doi.org/10.1182/blood-2024-204007

Published: 2024

Journal Articles

Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1-3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study

Sosana Delimpasi, Meletios A. Dimopoulos, Jan Straub, Argiris Symeonidis, Roman Hájek, Cyrille Touzeau, Viralkumar K. Bhanderi, Jesus Berdeja, Petr Pavlíček, Jeffrey V. Matous, Pawel J. Robak, Kaveri Suryanarayan, Miguel Villareal, Dasha Cherepanov, Jaydeep K. Srimani, Huilan Yao, Richard Labotka, Robert Z. Orlowski

Blood (2022) 140 (Supplement 1): 9995–9997.

https://doi.org/10.1182/blood-2022-163092

Published: 2022

Journal Articles

A Phase 1/2 Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, PK and Efficacy of ZN-d5, a Novel BCL-2 Inhibitor, for Treatment of Subjects with Relapsed/Refractory AL Amyloidosis

Efstathios Kastritis, Jeffrey V. Matous, Emad Uddin Abro, P. Taylor Eves, Cheng Zheng, Tony Fiorino, Jesus Berdeja

Blood (2022) 140 (Supplement 1): 4438–4439.

https://doi.org/10.1182/blood-2022-158617

Published: 2022

Journal Articles

Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

Sham Mailankody, Jeffrey V. Matous, Michaela Liedtke, Surbhi Sidana, Olalekan O. Oluwole, Meera Mohan, Jose C. Cruz, Rajneesh Nath, Faiz Anwer, Adriana Rossi, Myo Htut, Shahbaz A. Malik, Srinivas Ghatta, Myles Dillon, Wendy Ying, Lynn Navale, Erin E. Karski, Arun Balakumaran, Shaji K. Kumar

Blood (2022) 140 (Supplement 1): 4620–4622.

https://doi.org/10.1182/blood-2022-158231

Published: 2022

Journal Articles

Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study

Emma Searle, Hang Quach, Sandy W. Wong, Luciano J. Costa, Cyrille Hulin, Wojciech Janowski, Jesus Berdeja, Sébastien Anguille, Jeffrey V. Matous, Cyrille Touzeau, Anne-Sophie Michallet, Marla Husnik, Deeksha Vishwamitra, Zhuolu Niu, Julie Larsen, Lingling Chen, Jenna D. Goldberg, Rakesh Popat, Andrew Spencer

Blood (2022) 140 (Supplement 1): 394–396.

https://doi.org/10.1182/blood-2022-159711

Published: 2022

Journal Articles

Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Blood (2022) 140 (Supplement 1): 7264–7266.

https://doi.org/10.1182/blood-2022-157525

Published: 2022

Journal Articles

Single-Cell RNA-Sequencing Identifies Immune Biomarkers of Response to Immunotherapy in Patients with High-Risk Smoldering Myeloma

Blood (2021) 138 (Supplement 1): 330.

https://doi.org/10.1182/blood-2021-147623

Published: 2021

Journal Articles

A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

Blood (2021) 138 (Supplement 1): 1649.

https://doi.org/10.1182/blood-2021-149797

Published: 2021

Journal Articles

A Phase 1 Study of CFT7455, a Novel Degrader of IKZF1/3, in Multiple Myeloma and Non-Hodgkin Lymphoma

Jesus Berdeja, Sikander Ailawadhi, Steven M. Horwitz, Jeffrey V. Matous, Neha Mehta-Shah, Thomas Martin, Eli Muchtar, Paul G. Richardson, Shambavi Richard, Manisha Bhutani, Andrew J. Yee, Michael R. Palmer, Cathleen Gorman, Oliver Schoenborn-Kellenberger, Sanela Bilic, Adam Crystal, Michelle Mahler, Sagar Lonial

Blood (2021) 138 (Supplement 1): 1675.

https://doi.org/10.1182/blood-2021-153575

Published: 2021

Journal Articles

Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 651.

https://doi.org/10.1182/blood-2021-145572

Published: 2021

Journal Articles

Preliminary Clinical Response Data from a Phase 1b Study of Mavorixafor in Combination with Ibrutinib in Patients with Waldenström's Macroglobulinemia with MYD88 and CXCR4 Mutations

Steven P. Treon, Christian Buske, Sheeba K Thomas, Jorge J. Castillo, Andrew R. Branagan, Meletios A. Dimopoulos, Maria Gavriatopoulou, Diego Cadavid, Felix T Garzon, Weihua Tang, Sean Seyffert, Varun Garg, Shariq Ali, Arthur G. Taveras, Kelly Chen, Jeffrey V. Matous

Blood (2021) 138 (Supplement 1): 1362.

https://doi.org/10.1182/blood-2021-144706

Published: 2021

Journal Articles

Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma

Sham Mailankody, MBBS, Jeffrey V. Matous, MD, Michaela Liedtke, MD, Surbhi Sidana, MD, Shahbaz Malik, MD, Rajneesh Nath, MD, Olalekan O. Oluwole, MBBS, MPH, Erin E. Karski, Wade Lovelace, Xiangdong Zhou, PhD, Srinand Nandakumar, PhD, Arun Balakumaran, MD PhD, Parameswaran Hari, MD MRCP

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-140641

Published: 2020

NARROW

Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Majestec-2 Cohort a and Trimm-2 Studies

MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial

Analysis of Repeat Step-up Dosing and Cytokine Release Syndrome Events Following Prolonged Dosing Intervals of Teclistamab in the Phase 1/2 Majestec-1 Study

Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies

Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide

Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC TM Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Phase II Study of Isatuximab, and Weekly Carfilzomib + Dexamethasone in Relapsed and Refractory Multiple Myeloma (RRMM)

Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Combination with Daratumumab and Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma: Safety and Efficacy Results from the Phase 1b Monumental-2 Study

Higher Teclistamab Step-up Dosing in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Results from the Majestec-1 Trial

Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1-3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study

A Phase 1/2 Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, PK and Efficacy of ZN-d5, a Novel BCL-2 Inhibitor, for Treatment of Subjects with Relapsed/Refractory AL Amyloidosis

Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study

Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Single-Cell RNA-Sequencing Identifies Immune Biomarkers of Response to Immunotherapy in Patients with High-Risk Smoldering Myeloma

A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

A Phase 1 Study of CFT7455, a Novel Degrader of IKZF1/3, in Multiple Myeloma and Non-Hodgkin Lymphoma

Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

Preliminary Clinical Response Data from a Phase 1b Study of Mavorixafor in Combination with Ibrutinib in Patients with Waldenström's Macroglobulinemia with MYD88 and CXCR4 Mutations

Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only